DYRK1A/B inhibitor; prodrug form of INDY (Cat. No. 4997). Cell permeable. Inhibits phosphorylation of tau protein and rescues repressed calcineurin/NFAT signaling. Recovers Xenopus embryos from head malformation induced by DYRK1A overexpression in vivo.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 277.34. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.61 mL||18.03 mL||36.06 mL|
|5 mM||0.72 mL||3.61 mL||7.21 mL|
|10 mM||0.36 mL||1.8 mL||3.61 mL|
|50 mM||0.07 mL||0.36 mL||0.72 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Ogawa et al (2010) Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A. Nat.Commun. 1 86 PMID: 20981014
If you know of a relevant reference for ProINDY, please let us know.
View Related Products by Product Action
Keywords: ProINDY, supplier, downs, syndrome-related, kinases, Dyrk1A/B, inhibitors, inhibits, tau, phosphorylation, hyperphosphorylation, calcineurin, NFAT, neural, stem, cells, DYRK, Tocris Bioscience
1 Citation for ProINDY
Citations are publications that use Tocris products. Selected citations for ProINDY include:
Seu et al (2015) Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection. Sci Rep 89 6656 PMID: 25878110
Do you know of a great paper that uses ProINDY from Tocris? If so please let us know.
Literature in this Area
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.